Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization

References

Page 1

	Year	Citations
Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor Salvatore Siena, Marco Bregni, Bruno Brando, Blood	1989	537
Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Luen Bik To, Marion M. Roberts, David N. Haylock, PubMed	1992	414
A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells LB To, DN Haylock, Tracey L. Dowse, Blood	1994	190
Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol Luka Milas, Nancy Hunter, Belma Kurdoglu, Cancer Chemotherapy and Pharmacology Murine MammaryMedicineApoptosisPharmacologyCell Death	1995	181
Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor S Neben, Karen J. Marcus, Peter Mauch Blood	1993	151
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. M Markman, Thomas Hakes, R. Barakat, Journal of Clinical Oncology	1996	51
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. Taner Demirer, S Rowley, CD Buckner, Journal of Clinical Oncology	1995	48
Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Federico Innocenti, Romano Danesi, Antonello Di Paolo, Drug Metabolism and Disposition	1995	43
Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. D. Fennelly, Jeffrey Schneider, D. Spriggs, Journal of Clinical Oncology	1995	43
Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates KR Meehan, UN Verma, Ronan A. Cahill, Bone Marrow Transplantation Dose LevelCell TherapyBreast OncologyTransplantationMarrow Transplantation	1997	28

Page 1